SBRT for pancreatic cancer: In regard of Bohoudi et al.

SBRT for pancreatic cancer: In regard of Bohoudi et al. Radiother Oncol. 2018 May 03;: Authors: Garibaldi C, Moretti E, Russo S, Talamonti C, Villaggi E, Mancosu P, Italian Medical Physicists SBRT Working Group PMID: 29731159 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research

Related Links:

Publication date: Available online 13 October 2019Source: Seminars in Cancer BiologyAuthor(s): Vikram Shaw, Suyash Srivastava, Sanjay K. SrivastavaAbstractThe recent development of high throughput compound screening has allowed drug repurposing to emerge as an effective avenue for discovering novel treatments for cancer. FDA-approved antipsychotic drugs fluspirilene, penfluridol, and pimozide are clinically used for the treatment of psychotic disorders, primarily schizophrenia. These compounds, belong to diphenylbutylpiperidine class of antipsychotic drugs, are the potent inhibitors of dopamine D2 receptor and calcium chan...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
A new Yale-developed immunotherapy system has been shown to reduce or eliminate melanoma and triple-negative breast and pancreatic tumors in mice.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
In conclusion, spironolactone is a safe candidate drug that exerts anti-cancer effects in combination with non-DNA-damaging drugs, such as gemcitabine and osimertinib, most likely through the suppression of survivin.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Molecules, Vol. 24, Pages 3693: Metabolism, Transport and Drug–Drug Interactions of Silymarin Molecules doi: 10.3390/molecules24203693 Authors: Xie Zhang Zhang Yuan Silymarin, the extract of milk thistle, and its major active flavonolignan silybin, are common products widely used in the phytotherapy of liver diseases. They also have promising effects in protecting the pancreas, kidney, myocardium, and the central nervous system. However, inconsistent results are noted in the different clinical studies due to the low bioavailability of silymarin. Extensive studies were conducted to explore the metabo...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
We describe a contiguous gene deletion of the ATM locus in a multi-generation family of Italian descent with a strong family history of pancreatic cancer. A deletion of one copy of the entire ATM gene was identified by routine panel testing and further characterized by chromosomal microarray analysis. An 11q22.3 microdeletion of approximately 960kb was identified that is predicted to result in loss of 10 genes including ATM. The deletion was identified in two additional family members including a presymptomatic daughter and an affected sibling. A normal disomic complement of the 11q22.3 region was detected in a third famil...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Publication date: Available online 11 October 2019Source: The American Journal of SurgeryAuthor(s): Dhruv J. Patel, Waseem Lutfi, Patrick Sweigert, Emanuel Eguia, Gerard Abood, Lawrence Knab, Paul C. Kuo, Marshall S. BakerAbstractBackgroundPrior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered.MethodsWe queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy.Results29...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
CONCLUSIONS: Increased expression of miR-233 was associated with CDDP resistance in pancreatic cancer cells. Inhibition of miR-223 expression upregulated FoxO3a expression, restrained pancreatic cancer cell proliferation, promoted cell apoptosis, and enhanced CDDP sensitivity in pancreatic cancer cells. PMID: 31599414 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 10 October 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Béchade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Christophe Locher, Nicolas Williet, Jérôme Desrame, Pascal Artru, Emilie Soularue, Bertrand Le Roy, Julien TaiebSummaryBackgroundA combination of nab-paclitaxel plus gemcitabine (N + G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no publish...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
Contributors : Po-Hsien Huang ; Yan-Shen ShanSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensHumanMethylation 450K microarrays were used to identify aberrant DNA methylation in pancreatic adenocarcinoma (n=14), juice-circulating cancer cells (n=4), cancer associated fibroblasts (n=3), against adjacent normal pancreatic tissues (n=7)Bisulphite converted DNA from the 28 samples were hybridised to the Illumina HumanMethylation450 Beadchip v1.2
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by genome tiling array Homo sapiens Source Type: research
Leone Aglietta Surgical resection remains the only treatment that offers a potential chance of long-term survival. Unfortunately, about 80% of patients treated with curative intent will develop recurrence. Since 2001, adjuvant therapy with gemcitabine or 5-fluorouracyle was recommended. This approach allows a median overall survival (OS) of around 23 months, and 5-year survival of 22%. In recent years, two phase-3 trials investigating new chemotherapy regimens resulted in considerably improved survival times. The doublet gemcitabine–capecitabine has shown improvement in OS from 25.5 to 28 months (p = 0...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Italy Health | Pancreas | Pancreatic Cancer | Physics | Radiology